Andrew S. Dunn
- PROFESSOR Medicine, Hospital Medicine
American Board of Internal Medicine
- Hospital Medicine
MD, New York University
Internship, Internal Medicine
Mount Sinai Hospital
Residency, Internal Medicine
Mount Sinai Hospital
- Anticaogulation and Thrombosis
- Outpatient Deep Vein Thrombosis Treatment
- Mathematical Modelling of Warfarin Dose Adjustments
- Director, The Mount Sinai Hospital Outpatient DVT Treatment Program
- Director, Early Discharge on Warfarin Program
- Community Acquired Pneumonia Clinical Pathways Project
- Director, Primary Care Anticoagulation Service
Dr. Dunn received his medical degree at the New York University School of Medicine. He performed his internship and residency at Mount Sinai Medical Center and stayed on as faculty after completion. He is currently professor of Medicine and Director of the Hospitalist Service in the Department of Medicine. His research interests are in anticoagulation and thrombosis, most specifically in venous thromboembolism, atrial fibrillation, and the perioperative management of warfarin. Dr. Dunn has collaborated and led national studies in this field, including a multicenter North American study on the perioperative management of oral anticoagulation. He lectures nationally on various topics in anticoagulation and has written numerous journal articles, including perioperative bridging therapy, outpatient treatment of deep vein thrombosis, and the prevention of venous thromboembolism for medical inpatients. His work has been published in the American Journal of Medicine, Archives of Internal Medicine, Journal of Thrombosis and Thrombolysis, and Thrombosis and Haemostasis. In addition, Dr. Dunn is a co-author of the American College of Chest Physician’s guidelines on anticoagulation and thrombosis. Dr. Dunn is a Fellow of the American College of Physicians, a Fellow of the Society of Hospital Medicine, and a member of the Society of General Internal Medicine and the International Society of Thrombosis and Haemostasis.Clinical Interests
Team Award, Hospitalist Service
Mount Sinai Hospital
Healthcare Quality Award, Hospitalist Service
Mount Sinai Department of Medicine
House Staff Ambulatory Preceptor Award
- Site Director, Peripheral Arterial Disease Detection Project (PAD PARTNERS) - Director for one of 15 sites in a multicenter trial of peripheral arterial disease screening.
- Site Director, MATISSE DVT and PE trials. International randomized trials of DVT and PE treatment.
- Principal Investigator - Outpatient DVT Treatment Using LMWH. Prospective cohort study of outpatient DVT treatment with LMWH.
- Principal Investigator - Mathematical Modeling of Warfarin Dose. Derivation and validation of a model for warfarin dosage adjustments.
- Principal Investigator - Effect of Warfarin Titration on Delay of Discharge.
- Principal Investigator - The Use of Low-molecular-weight Heparin in the Perioperative Period for Patients on Long-term Warfarin.
Anticoagulation and thrombosis, including prophylaxis and treatment of DVT and PE, and perioperative management of warfarin
Dunn A, Turpie AG G. Perioperative management of patients on oral anticoagulants: a systematic review.. Arch Intern Med. 2009; 163: 901-908.
Dunn A, Bioh D, Beran M, Capasso M, Siu A. The impact of intravenous heparin administration on duration of hospitalization. . Mayo Clinic Proc. 2004; 79: 159-163.
Dunn A, Ho W, Wisnivesky J, Moore C, McGinn T, Sacks HS. Perioperative management of patients on oral anticoagulants: a decision-analysis. . Medical Decision-Making. 2005; 25: 387-397.
Dunn AS, Kaboli K, Chan H, Hubert R, White RH. Do patients followed in anticoagulation clinics for antiphospholipid antibody syndrome meet criteria for the disorder? . Thromb Haem. 2005; 94: 548-554.
Dunn A, Brenner K, Halm E. The magnitude of an iatrogenic disorder: A systematic review of the incidence of venous thromboembolism for general medical inpatients . Thromb Haem. 2006; 95: 758-762.
Dunn A, Spyropoulos AC, Turpie AG G. Bridging therapy in patients on long-term oral anticoagulant therapy who require surgery: the Prospective Perioperative Enoxaparin Cohort Trial (PROSPECT).. J Thromb Haem. 2007; 5: 2211-2218.
Douketis JD, Berger PB, Dunn AS. The perioperative management of antithrombotic therapy. American College of Chest Physicians evidence-based practice guidelines (8th edition).. Chest 2008; 133: 299-339S.
Dunn A. . Hospital medicine in high-def: The importance of defining the local mission of hospitalist groups. . Mount Sinai J Med 2008; 75: 415-417.
Dunn A, Markoff B. Physician-physician communication: What’s the hang-up? . J Gen Intern Med 2009; 24: 437-439.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Dunn did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
One Gustave L. Levy Place
New York, NY 10029